Forget Crispr Therapeutics: This Gene-Editing Pick Attracts
The gene-editing field is maturing from hype to real profits. This article outlines why a broader set of players coul...
Evaluating the effectiveness of zero based budgeting against traditional methods can guide your financial decisions. Explore which works best.
20,160 articlesThe gene-editing field is maturing from hype to real profits. This article outlines why a broader set of players coul...
A rising stake in Instacart highlights how investment groups are pricing the shift to digital grocery. This article e...
A mid-2026 pullback in amazon stock pulled back has investors weighing growth ambitions against profitability. This g...
Oracle’s 2026 story blends a sharp stock pullback with strong earnings momentum. Learn what’s driving the 18% drop, w...
Hong Kong’s RedotPay is exploring a fundraising round of up to $150 million ahead of a potential U.S. IPO, according ...
Inside ENAVATE's disclosed stake in Zenas BioPharma and why the Obexelimab pipeline is grabbing attention. Learn what...
SoFi faced a high-profile attack from a famed short-seller, sending shares lower. This deep dive explains what the re...
As JJSF prepares for its 2026 earnings call, investors will scrutinize margins, pricing power, and capital allocation...
Smart hosts don’t rely on a single channel. This guide explores niche platforms beyond airbnb, how they boost cash fl...
AST SpaceMobile is rebounding with a $1.2 billion contracted commitments milestone and expanding carrier partnerships...
As oil costs climb, ETH faces renewed pressure, illustrating a rare inverse relationship that market trackers say cou...
A dramatic 41% weekly jump has investors buzzing about Infleqtion. Learn what fueled the move, how to evaluate quantu...